What happens when a board-certified physician gets fed up spending half his day sorting through insurance PDFs? He builds a $490 billion solution.

In this revealing episode, Shane Speirs, MD, MBA—CEO of Adageis—pulls back the curtain on how his fintech AI platform is capturing the massive wave of value-based care adoption sweeping through healthcare. With over 580,000 patient lives already on the platform and aggressive growth targets ahead, Speirs breaks down the economics that make investors pay attention.

WATCH NOW!

You'll discover:

• Why Adageis's per-provider-per-month SaaS model is perfectly positioned for the value-based care transition
• How their patented Risk Engine and AI Scribe technology create defensible competitive advantages
• The strategy behind their AthenaHealth marketplace partnership and what it means for customer acquisition costs
• Details on their medical receivables financing model and how it diversifies revenue streams
• Real numbers: from 150,000 to 580,000 patient lives—what's driving this 4x growth trajectory

If you're looking to understand where healthcare technology meets tangible ROI, this conversation delivers. Speirs doesn't just talk about disrupting healthcare—he's living it, scaling it, and making it profitable.

The future of healthcare finance is here. Are you positioned to capitalize on it?

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned. The content of this podcast does not constitute investment, legal, or tax advice.

Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions. Past performance is not indicative of future results.

The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements.

Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate. By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.

What happens when you combine AI-powered robotics with strategic hotel acquisitions? You get Nightfood Holdings (OTCQB: NGTF)—a company pioneering a first-of-its-kind dual growth engine that's catching serious investor attention.

In this episode, President Ried Floco and CEO Jimmy Chan reveal how NGTF is leveraging 35+ years of hospitality expertise to deploy Robotics-as-a-Service (RaaS) solutions in real-world environments before scaling across multiple industries. Unlike pure-play tech companies, Nightfood owns its testing grounds—acquiring hotels that serve as innovation hubs while generating asset-backed revenue.

Key Investment Highlights Discussed:

• Why NGTF's operational-first approach beats tech-first competitors
• The strategic advantage of owned deployment sites for validation and credibility
• How the company positions itself at the intersection of two massive markets: the ~$107B service robotics sector and the ~$181B smart hospitality market
• The 3-5 year vision for portfolio expansion and cross-industry RaaS scaling
• Risk mitigation through tangible real estate assets paired with subscription revenue

Whether you're evaluating early-stage automation plays or looking for differentiated exposure to the robotics revolution, this conversation offers rare insight into a company building infrastructure for the future of work—one hotel at a time.

Perfect for: Growth investors, automation sector analysts, hospitality tech enthusiasts, and anyone tracking the convergence of AI, robotics, and real asset acquisition strategies.

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned.

The content of this podcast does not constitute investment, legal, or tax advice. Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions.

Past performance is not indicative of future results. The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements.

Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.

By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.

Kyle Samani didn't just invest in Solana—he's building the blueprint for how public companies will operate in the on-chain era. As Chairman of Forward Industries (NASDAQ: FORD) and co-founder of Multicoin Capital, Samani led a audacious pivot: transforming a legacy accessories company into the largest publicly traded Solana treasury, backed by a $1.65 billion war chest and over 6.8 million SOL.

In this episode, we dive deep into the mechanics behind this unprecedented strategy. Samani breaks down how Forward generates yield through staking and DeFi, why they're growing SOL-per-share instead of dollar returns, and what it means to tokenize equity on a blockchain. We challenge him on the risks: What happens if Solana doesn't become the backbone of global capital markets? How do you navigate regulators when your treasury is actively deployed in decentralized protocols? And at what price does issuing more equity become dilutive to shareholders?

This isn't MicroStrategy 2.0—it's something entirely new. Whether you're a crypto native, a public markets investor, or just curious about the future of corporate treasury management, this conversation will change how you think about the intersection of traditional finance and blockchain infrastructure.

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned.

The content of this podcast does not constitute investment, legal, or tax advice. Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions.

Past performance is not indicative of future results. The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements.

Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.

By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.

Discover how Beeline Holdings (NASDAQ: BLNE) is rewriting the rules of mortgage lending in a down market. CEO Nick Liuzza reveals the strategy behind achieving 38% loan origination growth while competitors managed just 9%, all while navigating toward profitability by early 2026.

In this investor-focused conversation, Liuzza breaks down Beeline's multi-pronged approach: their Bob 2.0 AI chatbot delivering 6x lead conversion at near-zero marginal cost, the MagicBlocks spin-out bringing enterprise AI sales agents to the broader mortgage industry, and the groundbreaking BeelineEQUITY product offering homeowners interest rate-neutral liquidity alternatives. Learn how strategic partnerships with vacation rental platforms are creating non-traditional origination channels, and why the company's capital strategy focuses on organic growth over dilution. With analyst price targets suggesting 200%+ upside potential and a clear roadmap from $6.9M quarterly losses to breakeven, this episode offers critical insights for investors evaluating high-growth fintech opportunities in a challenging mortgage environment.

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned.

The content of this podcast does not constitute investment, legal, or tax advice. Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions.

Past performance is not indicative of future results. The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements.

Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.

By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.

From Rejection to $200M Surge:

CEO Tony Giardini reveals how a dramatic White House reversal transformed Trilogy Metals overnight—from permit rejection to a $35.6M government investment that sent shares soaring 200%. Discover why Alaska's copper-cobalt-zinc deposits are suddenly America's critical minerals priority and what it means for investors in the green economy rush.

Watch Full episode on YouTube: https://youtu.be/TCV6P3hDRaw

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned.

The content of this podcast does not constitute investment, legal, or tax advice. Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions.

Past performance is not indicative of future results. The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements.

Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.

By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.

The private credit market has hit a tipping point—but success isn't just about having capital anymore. Matt Schwartz, US Finance Practice Group Leader at DLA Piper, reveals why 90% of private credit deals are sourced through internal relationships rather than intermediaries, and how AI is reshaping deal origination without replacing the human connection.

In this episode hosted by Carmel Fisher, discover why the current market creates a stark "have and have-nots" divide between companies with recent equity raises and those seeking creative financing solutions.

Matt breaks down how funds are using technology to identify amortization walls and maturity events, why it's "extremely hard to be an introvert" in today's deal sourcing environment, and what the potential M&A revival means for private credit.

Key takeaways for lenders and borrowers:

• How AI tools are narrowing the deal funnel internally
• Why relationship-building remains the ultimate competitive advantage
• Creative financing options for previously "unfinanceable" assets
• Strategic preparation needed for Q4 2025 market conditions

Whether you're a private credit fund looking to optimize sourcing strategies or a company exploring debt financing options, this conversation provides insider perspective on navigating an increasingly complex but opportunity-rich market.

Want access to Private Credit lenders?

Attend the Private Credit Sourcing Conference on October 20-21, at the Hard Rock Hotel in NYC.

Qualifying companies attend at no charge.

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned.

The content of this podcast does not constitute investment, legal, or tax advice. Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions.

Past performance is not indicative of future results. The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements.

Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.

By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.

Essential listening for biotech investors: Host Carmel Fisher interviews Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), who has a proven track record of generating multi-billion dollar returns in biotech.

Investment Thesis: Dr. Trieu previously delivered $2.9 billion (Abraxane®/Celgene) and $1.3 billion (Cynviloq™/NantPharma) exits.

His 500+ filed patents and 75 issued patents now anchor Oncotelic's competitive moat—a rare combination of proven value creation and late-stage asset positioning that most biotechs lack.

Key Investment Differentiators:

• Late-stage pipeline risk mitigation: Multiple assets approaching commercialization vs. typical early-stage biotech burn rates
• IP fortress strategy: Deep tumor microenvironment expertise creates defensible competitive barriers
• Accelerated regulatory pathways: Proprietary approach delivers "shortest timeline, highest chance of approval"
• Portfolio diversification: Oncology, rare diseases, and pediatric programs targeting multi-billion dollar addressable markets

Near-term Catalysts (Next 12 Months): Dr. Trieu confirms: "Our investors should be really looking forward to a lot of announcements... both from the clinical side as well as regulatory milestones such as IND approval, expansion into other indications, and partnership announcements."

Investment Opportunity: Unlike speculative biotech plays, Oncotelic combines validated leadership with late-stage assets and multiple value inflection points. Dr. Trieu explains how 25 years of operational execution experience translates into superior capital efficiency and reduced development risk.

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned. The content of this podcast does not constitute investment, legal, or tax advice.

Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions. Past performance is not indicative of future results.

The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements. Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.

By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.

From 2% to 50% Over Goal: How Women-Led CPG Brands Are Rewriting Venture Capital Rules

Despite women starting nearly half of all businesses in the US, less than 2% of venture capital funding goes to female founders. But Carrie Colbert, CEO and founder of Curate Capital, is changing that equation—and proving there's serious money to be made in the process.

In this episode, Carmel Fisher sits down with former petroleum engineer turned VC powerhouse Carrie reveals how she built a fund that overshot its fundraising goal by 50% by focusing exclusively on women-led consumer brands. She breaks down her "influential investment" model that turns influencers into equity partners, explains why CPG brands need more than pretty packaging to scale, and shares the four key categories driving returns in consumer goods.

Key insights for CPG founders and brands seeking funding:

• Why owning your supply chain matters more than viral marketing
• The late seed/early Series A funding sweet spot and what investors look for
• How to build "intrinsic value" that makes your brand acquisition-ready
• Real examples from portfolio companies solving everyday problems (from epidural accuracy to inclusive beauty)
• The insider criteria VCs use to evaluate consumer brands

Perfect for: CPG founders seeking venture capital, consumer brand executives exploring funding options, and anyone curious about the intersection of influencer marketing and venture investing.

Whether you're building the next breakthrough beauty brand or revolutionizing home products, Carrie's practical advice on building fundable businesses could be the difference between bootstrapping forever and scaling with serious capital backing.

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned. The content of this podcast does not constitute investment, legal, or tax advice.

Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions. Past performance is not indicative of future results.

The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements. Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.

By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.

Join us for an exclusive interview with Gareth Sheridan, CEO and Co-Founder of Nutriband Inc. (NASDAQ: NTRB), in what may be one of his final interviews before temporarily stepping aside to run for President of Ireland.

We dive deep into the company's groundbreaking AVERSA technology and its path to becoming the world's first abuse-deterrent transdermal patch.

What You'll Learn:

• How AVERSA technology could revolutionize opioid safety while preserving patient access to critical pain medications
• The strategic significance of Nutriband's exclusive partnership with Kindeva Drug Delivery and what it means for commercialization timelines
• Why analysts project AVERSA Fentanyl could capture $200-500M in peak annual sales
• How the company's unique regulatory pathway could slash traditional drug development costs and timelines
• BREAKING: Fresh insights on Nutriband's recent $5.3M warrant exercise and what this capital infusion means for their 2025 clinical milestones
• EXCLUSIVE: Sheridan's perspective on leadership transition as Co-Founder Serguei Melnik takes over as interim CEO during the Irish Presidential campaign

Sheridan reveals the company's ambitious 2025 roadmap, including plans for a pivotal Human Abuse Liability (HAL) clinical trial, and explains how Nutriband's manufacturing subsidiary is generating revenue while advancing their core pharmaceutical pipeline. With patents now secured across 46 countries and a 37% three-year return for investors, discover why this Orlando-based biotech believes they're positioned to capture a massive unmet need in pain management—and how the leadership transition will ensure continuity during this critical development phase.

Perfect for: Biotech investors, pharmaceutical industry professionals, and anyone interested in innovative solutions to the opioid crisis.

Key Topics: Abuse-deterrent drug technology, FDA regulatory pathways, biotech commercialization strategy, opioid market dynamics, pharmaceutical partnerships, executive leadership transitions

This episode was recorded just weeks before Sheridan's announcement to run for Irish President and step aside as CEO for the campaign period (September-October 2025).

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned. The content of this podcast does not constitute investment, legal, or tax advice.

Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions. Past performance is not indicative of future results.

The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements. Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.

By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.

The investment landscape is experiencing its most significant transformation since the birth of modern portfolio theory. As artificial intelligence reshapes every asset class and creates trillion-dollar market opportunities, institutional investors managing over $5+ trillion in combined AUM will converge at the most exclusive alternative investment gathering in North America.

The 7th Annual Beryl Elites Alternative Investment & Data Revolution Conference brings together 250+ carefully vetted attendees, including 75+ qualified allocators with direct investment authority. Unlike massive industry conferences where meaningful connections get lost in crowds, Beryl Elites ensures every conversation has billion-dollar potential.

Past speakers have included Anthony Scaramucci (SkyBridge Capital) and C-suite executives from NVIDIA, Morgan Stanley, Alphabet, Barclays, CNBC, and Fidelity—validation that when industry leaders need to understand AI's investment implications, they trust Beryl Elites to deliver actionable insights.

CURRENTLY OPEN TO SPONSORSHIPS.

Reach out today: [email protected]

Disclaimer:

The Harvest podcast is for informational and educational purposes only. The views and opinions expressed in this podcast are those of the hosts and guests and do not necessarily reflect the official policy or position of any company or institution mentioned. The content of this podcast does not constitute investment, legal, or tax advice.

Any strategies or investment ideas discussed may not be suitable for all investors. Listeners should conduct their own research and consult with professional advisors before making any investment decisions. Past performance is not indicative of future results.

The host, guests, and producers of this podcast may hold positions in the securities discussed. This podcast may contain forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those projected in these forward-looking statements. Investing in securities involves risk, including the potential loss of principal. Please be aware that the stock market can be volatile and investment values can fluctuate.

By listening to this podcast, you agree to not hold the host, guests, producers, or any affiliated companies liable for any investment decisions you make.

Always do your own due diligence and invest responsibly.